Avram Marc R, Cole John P, Gandelman Marcelo, Haber Robert, Knudsen Russell, Leavitt Matt T, Leonard Robert T, Puig Carlos J, Rose Paul T, Vogel James E, Ziering Craig L
Department of Dermatology New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, USA.
Dermatol Surg. 2002 Oct;28(10):894-900; discussion 900. doi: 10.1046/j.1524-4725.2002.02068.x.
Over the last decade surgical management of hair loss has become an increasingly popular and satisfying procedure for both men and women, as innovations in donor harvesting, graft size, and hairline design have resulted in consistently natural-appearing hair restoration.
In addition, a better understanding of the regulation of the hair-growth cycle has led to advances in the pharmacologic treatment of androgenetic alopecia.
Currently there are two U.S. Food and Drug Administration (FDA)-approved agents that promote hair regrowth: over-the-counter topical minoxidil solution for men and women and prescription oral finasteride tablets for men. In October 2001, a group of 11 international experts on hair loss and hair transplantation convened to review the physiology and effects of pharmacologic treatments of hair loss and to discuss the value of administering topical minoxidil therapy as an adjunct to hair transplantation.
This article presents the key findings and consensus points among the participants, including their current use of pharmacologic treatments, strategies for optimal results both pre- and postsurgery, and the importance of realistic patient expectations and compliance.
Based on the surgeons' clinical experience, the use of approved hair regrowth agents in hair transplant patients with viable but suboptimally functioning follicles in the region to be transplanted can increase hair density, speed regrowth in transplanted follicles, and complement the surgical result by slowing down or stopping further hair loss.
在过去十年中,脱发的外科治疗已成为一种越来越受男性和女性欢迎且令人满意的手术,因为在供体获取、移植毛囊大小和发际线设计方面的创新已带来始终自然的毛发修复效果。
此外,对毛发生长周期调节的更好理解推动了雄激素性脱发药物治疗的进展。
目前有两种美国食品药品监督管理局(FDA)批准的促进头发生长的药物:非处方外用米诺地尔溶液,男女均可使用;以及男性处方口服非那雄胺片。2001年10月,一组11位国际脱发及毛发移植专家召开会议,回顾脱发药物治疗的生理学及效果,并讨论外用米诺地尔疗法作为毛发移植辅助手段的价值。
本文介绍了参会者们的关键发现和共识要点,包括他们目前对药物治疗的使用情况、手术前后获得最佳效果的策略,以及患者现实期望和依从性的重要性。
基于外科医生的临床经验,在待移植区域毛囊存活但功能欠佳的毛发移植患者中使用已获批的头发生长药物,可增加毛发密度,加快移植毛囊的生长,并通过减缓或阻止进一步脱发来补充手术效果。